Fennec Pharmaceuticals Inc FENC
$9.57
▼ -3.43%
($-0.34)
🗓️ Earnings Next Week
Open
$9.65
Prev Close
$9.91
Day Range
$9.40 – $10.07
52W Range
$5.65 – $11.31
Market Cap
$332.43M
Beta
1.06
EPS (TTM)
$-0.28
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2001-06-05 |
| Shares Out. | 34,740,000 |
| Website | fennecpharma.com/ ↗ |
| Phone | 19196364530 |
| Employees | 35 |
| Revenue | $15.1M |
| Gross Profit | $14.5M |
| Net Income | $201,000 |
| Total Assets | $71.8M |
| Total Liabilities | $34.1M |
| Equity | $37.7M |
About Fennec Pharmaceuticals Inc
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Fennec Pharmaceuticals Inc is a publicly traded company under the ticker symbol FENC on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
12 analysts (2026-07-01)